{"id":866111,"date":"2025-07-02T09:06:30","date_gmt":"2025-07-02T13:06:30","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/windtree-announces-issuance-of-istaroxime-patent-for-the-united-states-for-acute-heart-failure\/"},"modified":"2025-07-02T09:06:30","modified_gmt":"2025-07-02T13:06:30","slug":"windtree-announces-issuance-of-istaroxime-patent-for-the-united-states-for-acute-heart-failure","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/windtree-announces-issuance-of-istaroxime-patent-for-the-united-states-for-acute-heart-failure\/","title":{"rendered":"Windtree Announces Issuance of Istaroxime Patent for the  United States for Acute Heart Failure"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <em>1.3 million patients are hospitalized annually in the U.S. from acute heart failure and it is the #1 cause of hospitalization in patients &gt;65 years old<\/em>\n      <\/p>\n<p align=\"center\">\n        <em>If istaroxime is approved in the US for acute heart failure, this patent would provide protection to 2039<\/em>\n      <\/p>\n<p>WARRINGTON, Pa., July  02, 2025  (GLOBE NEWSWIRE) &#8212; Windtree Therapeutics, Inc. (\u201cWindtree\u201d or the \u201cCompany\u201d) (NasdaqCM: WINT), a diversified company focused on revenue generation in multiple growing industries is pleased to announce that the United States Patent and Trademark Office has issued an istaroxime patent for the United States &#8211; application number 18\/150,870 directed to \u201cISTAROXIME-CONTAINING INTRAVENOUS FORMULATION FOR THE TREATMENT OF ACUTE HEART FAILURE.\u201d<\/p>\n<p>Acute heart failure, or AHF, impacts millions of patients globally and istaroxime has previously completed two positive Phase 2 AHF studies and two positive early cardiogenic shock studies caused by acute heart failure.<\/p>\n<p>\u201cWe are pleased to strengthen our intellectual property for istaroxime with this patent for the United States,\u201d said Jed Latkin, CEO of Windtree. \u201cIstaroxime is approaching Phase 3 readiness in cardiogenic shock and acute heart failure. If istaroxime is approved in AHF, this patent would provide protection until 2039. We believe the profile of istaroxime is differentiated from currently available drugs and drug treatment innovation is desired for patients.\u201d<\/p>\n<p>\n        <strong>About Istaroxime<\/strong><br \/>\n        <br \/>Istaroxime is a first-in-class dual-mechanism therapy designed to improve both systolic and diastolic cardiac function. Istaroxime is a positive inotropic agent that increases myocardial contractility through inhibition of Na+\/K+- ATPase with a complimentary mechanism that facilitates myocardial relaxation through activation of the SERCA2a calcium pump on the sarcoplasmic reticulum enhancing calcium reuptake from the cytoplasm. Data from multiple Phase 2 studies in patients with early cardiogenic shock or acute decompensated heart failure demonstrate that istaroxime infused intravenously can significantly improve cardiac function and blood pressure without increasing heart rate or the incidence of clinically significant cardiac rhythm disturbances.<\/p>\n<p>\n        <strong>About Windtree Therapeutics, Inc.<\/strong><br \/>\n        <br \/>Windtree Therapeutics, Inc. is a diversified company focused on becoming a revenue generating company in a multitude of growing industries to drive toward overall profitability.<\/p>\n<p>\n        <strong>Forward Looking Statements<\/strong><br \/>\n        <br \/>The Company may, in some cases, use terms such as \u201cpredicts,\u201d \u201cbelieves,\u201d \u201cpotential,\u201d \u201cproposed,\u201d \u201ccontinue,\u201d \u201cestimates,\u201d \u201canticipates,\u201d \u201cexpects,\u201d \u201cplans,\u201d \u201cintends,\u201d \u201cmay,\u201d \u201ccould,\u201d \u201cmight,\u201d \u201cwill,\u201d \u201cshould\u201d or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are based on information available to the Company as of the date of this press release and are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the Company\u2019s current expectations. Examples of such risks and uncertainties include, among other things: the Company\u2019s risks and uncertainties associated with the success and advancement of its product candidates; the Company\u2019s ability to manage costs and execute on its operational and budget plans; risks related to technology transfers to contract manufacturers and manufacturing development activities; delays encountered by the Company, contract manufacturers or suppliers in manufacturing drug products, drug substances, and other materials on a timely basis and in sufficient amounts; risks relating to regulatory requirements; risks related to the size and growth potential of the markets for the Company\u2019s product candidates, and the Company\u2019s ability to service those markets; the Company\u2019s ability to develop sales and marketing capabilities, whether alone or with potential future collaborators; the rate and degree of market acceptance of the Company\u2019s product candidates, if approved; the impacts of political unrest, including as a result of geopolitical tension, and any sanctions, export controls or other restrictive actions that may be imposed by\u00a0the United States\u00a0and\/or other countries which could have an adverse impact on the Company\u2019s operations, including through disruption in supply chain or access to potential international clinical trial sites. These and other risks are described in the Company\u2019s periodic reports, including its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, filed with or furnished to the\u00a0Securities and Exchange Commission\u00a0and available at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=jRErIZiyxXkE3wTZKmL6sF2Vj-5t4f2tJoaJErl20clQN4U65lvGLlg5ciBUNkddIX99_wZ64LDjqBBciS9qVA==\" rel=\"nofollow\" target=\"_blank\">www.sec.gov<\/a>. Any forward-looking statements that the Company makes in this press release speak only as of the date of this press release. The Company assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.<\/p>\n<p>\n        <strong>Contact Information:<\/strong><br \/>\n        <br \/>Eric Curtis<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ssZCjP5dGsy5MXiTuww5fdpTCh-7aOyzRErUA6iZnzvGTMTE-_n5FEu5ERYVKFu9PyxjEFcOlxQrV9-w2wHsf5YyWnfF3pmreX8bWDHhL28=\" rel=\"nofollow\" target=\"_blank\">ecurtis@windtreetx.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ4ODA2OCM3MDI4Njg3IzUwMDA3MzYyMA==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZWViYWMyMTktN2ZmOC00ZjdkLThkOTQtMjE4ZWE4M2RmMDZjLTUwMDA3MzYyMC0yMDI1LTA3LTAyLWVu\/tiny\/Windtree-Therapeutics.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>1.3 million patients are hospitalized annually in the U.S. from acute heart failure and it is the #1 cause of hospitalization in patients &gt;65 years old If istaroxime is approved in the US for acute heart failure, this patent would provide protection to 2039 WARRINGTON, Pa., July 02, 2025 (GLOBE NEWSWIRE) &#8212; Windtree Therapeutics, Inc. (\u201cWindtree\u201d or the \u201cCompany\u201d) (NasdaqCM: WINT), a diversified company focused on revenue generation in multiple growing industries is pleased to announce that the United States Patent and Trademark Office has issued an istaroxime patent for the United States &#8211; application number 18\/150,870 directed to \u201cISTAROXIME-CONTAINING INTRAVENOUS FORMULATION FOR THE TREATMENT OF ACUTE HEART FAILURE.\u201d Acute heart failure, or AHF, impacts millions of patients globally and &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/windtree-announces-issuance-of-istaroxime-patent-for-the-united-states-for-acute-heart-failure\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Windtree Announces Issuance of Istaroxime Patent for the  United States for Acute Heart Failure&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-866111","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Windtree Announces Issuance of Istaroxime Patent for the United States for Acute Heart Failure - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/windtree-announces-issuance-of-istaroxime-patent-for-the-united-states-for-acute-heart-failure\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Windtree Announces Issuance of Istaroxime Patent for the United States for Acute Heart Failure - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"1.3 million patients are hospitalized annually in the U.S. from acute heart failure and it is the #1 cause of hospitalization in patients &gt;65 years old If istaroxime is approved in the US for acute heart failure, this patent would provide protection to 2039 WARRINGTON, Pa., July 02, 2025 (GLOBE NEWSWIRE) &#8212; Windtree Therapeutics, Inc. (\u201cWindtree\u201d or the \u201cCompany\u201d) (NasdaqCM: WINT), a diversified company focused on revenue generation in multiple growing industries is pleased to announce that the United States Patent and Trademark Office has issued an istaroxime patent for the United States &#8211; application number 18\/150,870 directed to \u201cISTAROXIME-CONTAINING INTRAVENOUS FORMULATION FOR THE TREATMENT OF ACUTE HEART FAILURE.\u201d Acute heart failure, or AHF, impacts millions of patients globally and &hellip; Continue reading &quot;Windtree Announces Issuance of Istaroxime Patent for the United States for Acute Heart Failure&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/windtree-announces-issuance-of-istaroxime-patent-for-the-united-states-for-acute-heart-failure\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-02T13:06:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ4ODA2OCM3MDI4Njg3IzUwMDA3MzYyMA==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/windtree-announces-issuance-of-istaroxime-patent-for-the-united-states-for-acute-heart-failure\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/windtree-announces-issuance-of-istaroxime-patent-for-the-united-states-for-acute-heart-failure\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Windtree Announces Issuance of Istaroxime Patent for the United States for Acute Heart Failure\",\"datePublished\":\"2025-07-02T13:06:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/windtree-announces-issuance-of-istaroxime-patent-for-the-united-states-for-acute-heart-failure\\\/\"},\"wordCount\":737,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/windtree-announces-issuance-of-istaroxime-patent-for-the-united-states-for-acute-heart-failure\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ4ODA2OCM3MDI4Njg3IzUwMDA3MzYyMA==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/windtree-announces-issuance-of-istaroxime-patent-for-the-united-states-for-acute-heart-failure\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/windtree-announces-issuance-of-istaroxime-patent-for-the-united-states-for-acute-heart-failure\\\/\",\"name\":\"Windtree Announces Issuance of Istaroxime Patent for the United States for Acute Heart Failure - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/windtree-announces-issuance-of-istaroxime-patent-for-the-united-states-for-acute-heart-failure\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/windtree-announces-issuance-of-istaroxime-patent-for-the-united-states-for-acute-heart-failure\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ4ODA2OCM3MDI4Njg3IzUwMDA3MzYyMA==\",\"datePublished\":\"2025-07-02T13:06:30+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/windtree-announces-issuance-of-istaroxime-patent-for-the-united-states-for-acute-heart-failure\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/windtree-announces-issuance-of-istaroxime-patent-for-the-united-states-for-acute-heart-failure\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/windtree-announces-issuance-of-istaroxime-patent-for-the-united-states-for-acute-heart-failure\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ4ODA2OCM3MDI4Njg3IzUwMDA3MzYyMA==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ4ODA2OCM3MDI4Njg3IzUwMDA3MzYyMA==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/windtree-announces-issuance-of-istaroxime-patent-for-the-united-states-for-acute-heart-failure\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Windtree Announces Issuance of Istaroxime Patent for the United States for Acute Heart Failure\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Windtree Announces Issuance of Istaroxime Patent for the United States for Acute Heart Failure - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/windtree-announces-issuance-of-istaroxime-patent-for-the-united-states-for-acute-heart-failure\/","og_locale":"en_US","og_type":"article","og_title":"Windtree Announces Issuance of Istaroxime Patent for the United States for Acute Heart Failure - Market Newsdesk","og_description":"1.3 million patients are hospitalized annually in the U.S. from acute heart failure and it is the #1 cause of hospitalization in patients &gt;65 years old If istaroxime is approved in the US for acute heart failure, this patent would provide protection to 2039 WARRINGTON, Pa., July 02, 2025 (GLOBE NEWSWIRE) &#8212; Windtree Therapeutics, Inc. (\u201cWindtree\u201d or the \u201cCompany\u201d) (NasdaqCM: WINT), a diversified company focused on revenue generation in multiple growing industries is pleased to announce that the United States Patent and Trademark Office has issued an istaroxime patent for the United States &#8211; application number 18\/150,870 directed to \u201cISTAROXIME-CONTAINING INTRAVENOUS FORMULATION FOR THE TREATMENT OF ACUTE HEART FAILURE.\u201d Acute heart failure, or AHF, impacts millions of patients globally and &hellip; Continue reading \"Windtree Announces Issuance of Istaroxime Patent for the United States for Acute Heart Failure\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/windtree-announces-issuance-of-istaroxime-patent-for-the-united-states-for-acute-heart-failure\/","og_site_name":"Market Newsdesk","article_published_time":"2025-07-02T13:06:30+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ4ODA2OCM3MDI4Njg3IzUwMDA3MzYyMA==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/windtree-announces-issuance-of-istaroxime-patent-for-the-united-states-for-acute-heart-failure\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/windtree-announces-issuance-of-istaroxime-patent-for-the-united-states-for-acute-heart-failure\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Windtree Announces Issuance of Istaroxime Patent for the United States for Acute Heart Failure","datePublished":"2025-07-02T13:06:30+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/windtree-announces-issuance-of-istaroxime-patent-for-the-united-states-for-acute-heart-failure\/"},"wordCount":737,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/windtree-announces-issuance-of-istaroxime-patent-for-the-united-states-for-acute-heart-failure\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ4ODA2OCM3MDI4Njg3IzUwMDA3MzYyMA==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/windtree-announces-issuance-of-istaroxime-patent-for-the-united-states-for-acute-heart-failure\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/windtree-announces-issuance-of-istaroxime-patent-for-the-united-states-for-acute-heart-failure\/","name":"Windtree Announces Issuance of Istaroxime Patent for the United States for Acute Heart Failure - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/windtree-announces-issuance-of-istaroxime-patent-for-the-united-states-for-acute-heart-failure\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/windtree-announces-issuance-of-istaroxime-patent-for-the-united-states-for-acute-heart-failure\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ4ODA2OCM3MDI4Njg3IzUwMDA3MzYyMA==","datePublished":"2025-07-02T13:06:30+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/windtree-announces-issuance-of-istaroxime-patent-for-the-united-states-for-acute-heart-failure\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/windtree-announces-issuance-of-istaroxime-patent-for-the-united-states-for-acute-heart-failure\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/windtree-announces-issuance-of-istaroxime-patent-for-the-united-states-for-acute-heart-failure\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ4ODA2OCM3MDI4Njg3IzUwMDA3MzYyMA==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ4ODA2OCM3MDI4Njg3IzUwMDA3MzYyMA=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/windtree-announces-issuance-of-istaroxime-patent-for-the-united-states-for-acute-heart-failure\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Windtree Announces Issuance of Istaroxime Patent for the United States for Acute Heart Failure"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/866111","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=866111"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/866111\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=866111"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=866111"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=866111"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}